9PCB

Structure of Synaptic Vesicle Protein 2A Bound to UCB-J

This is a non-PDB format compatible entry.

Summary for 9PCB

• Entry DOI: 10.2210/pdb9pcb/pdb
• EMDB information: 71501
• Descriptor: Synaptic vesicle glycoprotein 2A, (4R)-1-[(3-methylpyridin-4-yl)methyl]-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one (2 entities in total)
• Functional Keywords: synaptic vesicle, slc22, pet tracer, membrane protein
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 1
• Total formula weight: 76639.36

Authors

Mittal, A.,Martin, M.F.,Ledecq, M.,Horanyi, P.S.,Coleman, J.A. (deposition date: 2025-06-27, release date: 2025-09-10, Last modification date: 2025-10-01)

Primary citation

Mittal, A.,Martin, M.F.,Provins, L.,Hall, A.,Ledecq, M.,Wolff, C.,Gillard, M.,Horanyi, P.S.,Coleman, J.A.
Mechanisms underlying allosteric modulation of antiseizure medication binding to synaptic vesicle protein 2A (SV2A).
Proc.Natl.Acad.Sci.USA, 122:e2510239122-e2510239122, 2025

PubMed Abstract: Brivaracetam (BRV) and levetiracetam (LEV) are antiseizure medications (ASMs); UCB-J is a PET tracer targeting synaptic vesicle protein 2A (SV2A); UCB7361 is closely related to padsevonil, an experimental anticonvulsant; while UCB1244283 acts as an allosteric modulator for BRV and LEV binding but not for these other ligands. The SV2A-BRV-UCB1244283 structure reveals how UCB1244283 allosterically enhances BRV binding by occupying an allosteric site near the primary binding site, preventing BRV dissociation. This allosteric site, formed by hydrophobic and uncharged residues, is an uncharacterized small-molecule binding site in SV2A. Structural analysis and mutagenesis demonstrate that an allosteric network between the primary and allosteric sites governs high-affinity ASM binding. Our studies suggest that UCB1244283 selectively binds SV2A over SV2B and SV2C, with specific mutations disrupting binding. Structures of SV2A-UCB-J and SV2A-UCB7361 show that UCB1244283 binding is only possible when the primary site ligand does not overlap with the allosteric site, and that repositioning of Ser601, Thr605, and Leu655 is critical for allosteric ligand binding. Structural comparison of multiple SV2A complexes reveals that primary site occupancy shapes the conformation of the lumenal half of the transmembrane domain, influencing how UCB1244283 binds via a connected network that differentially stabilizes TM1 in either an open or closed conformation and repositions key allosteric and primary site residues. These insights provide a foundation for developing therapeutics targeting the allosteric site and modulating SV2A function.

PubMed: 40892927
DOI: 10.1073/pnas.2510239122

Experimental method

ELECTRON MICROSCOPY (3.42 Å)